Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Shanghai Henlius Biotech, Inc. successfully passed an ordinary resolution during its 2024 extraordinary general meeting. The resolution, which involved key transactions under the HLX01 and HLX03 Agreements, saw a favorable vote from over 93% of the shareholders present. This outcome underscores the company’s strategic direction and shareholder support.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.